NCT06133556View on ClinicalTrials.gov

Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

October 20, 2028

Study Completion Date

October 20, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

MCBC regimen

using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d

DRUG

Bu/Cy regimen

control group, the standard conditioning regimen Busulfan/Cyclophosphamide

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER